


Prof. Philip Bufler, MD

1 | General information

Contact details: Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK)
Augustenburger Platz 1, 13353 Berlin

Tel.: +49 (0)30 450-516032
E-mail: philip.bufler@charite.de



Current position: Professor of Pediatrics (W3), Director, Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK)

Researcher unique identifier(s): ORCID-ID: 0000-0002-5742-8273

2 | Academic education

1988 – 1995 Medical School, Ludwig-Maximilians-University (LMU) Munich, (clinical electives: Guy's Hospital, London, UK; University of Chicago, Illinois, New York University, NY, USA)

3 | Advanced academic qualifications:

2006 Habilitation and *venia legendi*, Pediatrics, “Mechanisms of innate immunity: pulmonary collectins and cytokines of the Interleukin-1 family as examples of local and systemic effector molecules”, LMU Munich (Mentor: Dietrich Reinhardt)

1997 MD thesis “Soluble lipopolysaccharide receptor (CD14) is released via two different mechanisms from human monocytes and CD14 transfected cells” (*summa cum laude*), Institute for Immunology, LMU Munich (Supervisors: Hartmut Engelmann, Gerd Riethmüller)

4 | Postgraduate professional career:

Since 2017 Professor (W3) Pediatric Gastroenterology and Hepatology, Director, Charité – Universitätsmedizin Berlin, CVK

2013 Head, Pediatric Hepatology, LMU Munich

2009 German board certification *Allergology*

2007 Attending physician Pediatric Gastroenterology, Dr. von Hauner Children's Hospital, LMU Munich

2007 German board certification *Pediatric Gastroenterology*

2005 German board certification *Pediatrics*

2003 – 2005 Resident physician, Dr. von Hauner Children's Hospital, LMU Munich

2001 – 2003 Postdoctoral Research Fellowship (DFG), UCHSC Denver, Colorado, USA

1995 – 2000 Resident physician in Pediatrics, Kinderpoliklinik, LMU Munich

5 | Other:

Awards/Honors

- Postdoctoral Investigator Award, International Cytokine Society (2003)

Other professional activities:

- S3 Guideline coordinator: Pediatric Gastroenterology “Chronic Pancreatitis” (DGVS) (2010, 2020)
- Governing Board member and treasurer, Society for Pediatric Gastroenterology and Nutrition [Gesellschaft für pädiatrische Gastroenterologie und Ernährung (GPGE) (2009 – 2017)]

- Editorial board: *Frontiers in Immunology* (Associate Editor), *Mediators of Inflammation*, *Immune Network*,
- Guidelines: DGVS Crohn's disease, DGVS *H. pylori*, DGVS Autoimmune liver diseases, DGVS Pancreatitis, DGVS Hepatitis C

6 | Selected publications:

1. Griessmair L, Pirringer L, Mountford S, Sendlhofert A, Koletzko S, Mayr D, **Bufler P**. Expression of IL-37 Correlates With Immune Cell Infiltrate and Fibrosis in Pediatric Autoimmune Liver Diseases. **J Pediatr Gastroenterol Nutr** 2022; 74,doi: 10.1097
2. Mountford S, Effenberger M, Noll-Puchta H, Griessmair L, Ringleb A, Haas S, Denk G, Reiter FP, Mayr D, Dinarello CA, Tilg H, **Bufler P**. Modulation of Liver Inflammation and Fibrosis by Interleukin-37. **Front Immunol** 2021; 12,603649
3. Kalveram L, Schunck WH, Rothe M, Rudolph B, Loddenkemper C, Holzhutter HG, Henning S, **Bufler P**, Schulz M, Meierhofer D, Zhang IW, Weylandt KH, Wiegand S, Hudert CA. Regulation of the cytochrome P450 epoxygenase pathway is associated with distinct histologic features in pediatric non-alcoholic fatty liver disease. **Prostaglandins Leukot Essent Fatty Acids** 2021; 164,102229
4. Mountford S, Ringleb A, Schwaiger R, Mayr D, Kobold S, Dinarello CA, **Bufler P**. Interleukin-37 Inhibits Colon Carcinogenesis During Chronic Colitis. **Front Immunol** 2019; 10,2632
5. Hudert CA, Tzschatsch H, Rudolph B, Blaker H, Loddenkemper C, Muller HP, Henning S, **Bufler P**, Hamm B, Braun J, Holzhutter HG, Wiegand S, Sack I, Guo J. Tomoelastography for the Evaluation of Pediatric Nonalcoholic Fatty Liver Disease. **Invest Radiol** 2019; 54,198-203
6. Hudert CA, Selinski S, Rudolph B, Blaker H, Loddenkemper C, Thielhorn R, Berndt N, Golka K, Cadenas C, Reinders J, Henning S, **Bufler P**, Jansen PLM, Holzhutter HG, Meierhofer D, Hengstler JG, Wiegand S. Genetic determinants of steatosis and fibrosis progression in paediatric non-alcoholic fatty liver disease. **Liver Int** 2019; 39,540-556
7. Nold-Petry CA, Lo CY, Rudloff I, Elgass KD, Li S, Gantier MP, Lotz-Havla AS, Gersting SW, Cho SX, Lao JC, Ellisdon AM, Rotter B, Azam T, Mangan NE, Rossello FJ, Whisstock JC, **Bufler P**, Garlanda C, Mantovani A, Dinarello CA, Nold MF. IL-37 requires the receptors IL-18Ralpha and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. **Nat Immunol** 2015; 16,354-365
8. Bulau AM, Nold MF, Li S, Nold-Petry CA, Fink M, Mansell A, Schwerdt T, Hong J, Rubartelli A, Dinarello CA, **Bufler P**. Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses. **Proc Natl Acad Sci U S A** 2014; 111,2650-2655
9. Ballak DB, van Diepen JA, Moschen AR, Jansen HJ, Hijmans A, Groenhof GJ, Leenders F, **Bufler P**, Boekschoten MV, Muller M, Kersten S, Li S, Kim S, Eini H, Lewis EC, Joosten LA, Tilg H, Netea MG, Tack CJ, Dinarello CA, Stienstra R. IL-37 protects against obesity-induced inflammation and insulin resistance. **Nat Commun** 2014; 5,4711
10. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, **Bufler P**, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. **Nat Immunol** 2010; 11,1014-1022

Patents:

1. **Bufler P**, SooHyun Kim SH., Dinarello CA. Method of treatment using a cytokine able to bind IL-18BP to inhibit the activity of a second cytokine. 2009. United States Patent; US2009074710
2. Mascagni P, Leoni F, Porro G, Pagani P, Dona G, Pozzi P, Dinarello C, Fantuzzi G, Siegmund B, Reznikov L, **Bufler P**, Kim S-H, Pomeranz B. Histone deacetylase enzyme- inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti- inflammatory drugs. 2004. United States Patent; US2004157930